ArticleJournal of the Egyptian National Cancer Institute2026
Real-world efficacy and safety of CDK4/6 inhibitors plus endocrine therapy in HR+/HER2 - metastatic breast cancer: a single-institution experience.
Article in Journal of the Egyptian National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer is the most common type of advanced breast cancer. The addition of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors to endocrine therapy (ET) has made a marked change to patient outcomes. While clinical trials have established their efficacy, real-world studies like this one are needed to confirm their effectiveness given the many variables which may arise in patient demographics and clinical presentation.
methodsA retrospective study was conducted on patients with HR+/HER2 - metastatic breast cancer treated with palbociclib, ribociclib, or abemaciclib plus ET at Electricity Hospital, Cairo, Egypt, between January 2019 and January 2025. Data on demographics, clinical characteristics, and treatment outcomes were collected from medical records. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method, and prognostic variables were analyzed using Cox regression.
resultsA total of 59 patients (94.9% female; median age 58 years) were included. De novo metastatic disease was present in 39%, and visceral metastases in 33.9%. Ribociclib was prescribed to 52.5%, palbociclib to 39%, and abemaciclib to 8.5%. The objective response rate (ORR) was 88.1%, and the clinical benefit rate (CBR) was 98.3%. Median PFS was 23.7 months (95% CI, 11.9-23.9), and median OS was 38.9 months (95% CI, 27.0-60.3). On univariate analysis, absence of brain metastases, endocrine sensitivity, treatment response, and neutropenia were linked to longer PFS and OS. Dose reduction did not negatively impact outcomes. Toxicities were generally manageable, with grade 3-4 neutropenia in 33.9% of patients and no febrile episodes.
conclusionIn this real-world cohort, CDK4/6 inhibitors plus ET achieved survival outcomes similar to those reported in clinical trials, with a favorable safety profile. Endocrine sensitivity, absence of brain metastases, and development of neutropenia were associated with better survival, supporting the use of CDK4/6 inhibitors across a broad patient population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.